Mechanistically, AKT3-174aa inhibits GBM tumorigenicity by competitively interacting with phosphorylated 3-phosphoinositide-dependent protein kinase-1 (PDK1) and reducing the phosphorylation of AKT at Thr308, thus negatively regulating the PI3K/AKT signaling pathway [101]. This evidence concerns the gene AKT3 and glioblastoma.